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Background: CALGB 9633 is a randomized trial that randomized 
patients to observation (O) or 4 cycles of adjuvant chemotherapy 
with carboplatin and paclitaxel (C). A statistically signiﬁcant effect in 
favor of adjuvant chemotherapy was seen for failure-free survival and 
overall survival for tumors ≥ 4 cm. A laboratory companion study was 
conducted to see if additional prognostic information could be obtained 
from molecular and clinical factors. 
Methods: Parafﬁn blocks were obtained for 249 of the 344 patients 
randomized. Immunohistochemical (IHC) staining was successfully 
performed on 241 cases for bcl-2, p53, blood group antigen A and 
mucin and correlated with failure-free survival. 
Results: The prevalence of the markers was a follows: bcl-2 17% 
(O/C 15%/19%), p53 47% (42%/51%), blood group antigen A 25% 
(28%/23%) and mucin 46% (48%/42%). There are no statistically 
signiﬁcant associations between marker positivity and treatment arm 
(p>0.15). Analysis of failure-free survival (FFS) survival is shown 
below:
Marker Median FFS in months (95%CI) Log-rank
 negative positive p-value
bcl-2 66(54,98) 70(34,NR) 0.65
p53 98(57,NR) 63(37,88) 0.11
antigen A 88(52,NR) 67(54,NR) 0.88
mucin NR 51(28,NR) 0.0016
*NR=not reached
In multivariate analysis using a model with all 4 variables, a statisti-
cally signiﬁcant association between shorter FFS and mucin positive 
(p-value=0.0024; hazard ration (HR) 2.14) and p53 positive (p-value 
0.0057; HR 1.95) patients was seen. Gender and estimated tumor vol-
ume were also prognostic (p-value <0.05).
Conclusions: Preliminary analysis of the biological markers bcl-2, 
p53, blood group antigen A and mucin expression showed a statistically 
signiﬁcant association between shorter FFS and p53 and mucin IHC 
expression. Additional analysis including tumor size and lymph node 
sampling as well as effects on survival will be presented.
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Increased BRCA1 mRNA: an independent prognostic variable 
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Background: Following surgical resection in operable NSCLC, 5-year 
survival is 60% in stage I, 39% in stage IIB and 23% in stage IIIA, 
with relapse commonly as distant metastases. The average beneﬁt of 
adjuvant chemotherapy is 5%, ranging from nil in stage I to 15% in 
stage II-IIIA. Caretaker genes involved in keeping genetic alterations 
to a minimum include the nucleotide excision repair genes ERCC1 and 
myeloid zinc ﬁnger 1 (MZF1), which mediates ERCC1 expression, and 
other stability genes, such as BRCA1, which control processes involv-
ing large portions of chromosomes. Thioredoxin-1 (TRX1) is a redox 
protein overexpressed in NSCLC that is correlated with poor prognosis, 
and TWIST contributes to metastasis by promoting epithelial-mesen-
chymal transition. 
Methods: In order to identify p with a high risk of relapse, we inves-
tigated the expression of these 5 transcripts in frozen resected tumors 
from 126 resected NSCLC p by real-time quantitative PCR. Gene 
expression was normalized using a-actin and 18SrRNA expression as 
internal references. 
Results: Adenocarcinoma (adeno), 33 p; squamous cell carcinoma 
(SCC), 93 p. Stage: IA, 18 p; IB, 53 p; IIB, 33 p; IIIA, 22 p. Tumoral 
transcript expression with a-actin: ERCC1, 1.23; MZF1, 0.53; BRCA1, 
3.65; TRX1, 1.82; TWIST, 7.75. A strong correlation was observed 
between the expression of ERCC1, MZF1 and BRCA1 (P<0.001). 
Expression of each of the 5 transcripts was higher in SCC than in adeno 
(P<0.001). Median survival (MS): low ERCC1 (<1.5) = not reached 
(NR), high ERCC1 = 33 months (m) (P=0.21); low MZF1 (<0.5) = NR, 
high MZF1 = 33 m (P=0.04); low BRCA1 (<5) = NR, high BRCA1 = 
22 months (m) (P=0.01); low TRX1 (<0.8) = NR, high TRX1 = 39.5 
m (P=0.02); no differences in MS according to levels of TWIST. In 
a multivariate Cox model for survival, BRCA1 and stage emerged as 
independent prognostic variables (Table). 
Conclusion: Increased BRCA1 is associated with shorter survival, and 
BRCA1 assessment could be useful for customizing adjuvant chemo-
therapy.
 HR 95% CI p
Stage 
IA 1   
IIA- IIIA 1.75 1.02-3.06 0.04
BRCA Level 
<5 1   
<5 1.77 1.02-3.06 0.04
